Navigation Links
Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
Date:11/6/2012

under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies or as a standalone cancer therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to successfully defend its intellectual property portfolio in the United States or in the European Union, the Company's ability to realize commercial opportunities in the European Union, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commis
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
3. Aethlon Medical Note: Fiscal Year Revenue Guidance
4. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
5. Aethlon Medical to Present at Todays Security Research Associates 8th Annual Growth Conference
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
8. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
9. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
10. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
11. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Endo International plc (NASDAQ: ... quarter 2014 revenues of $719 million, an increase of ... $712 million. Endo reported net income of $21 million ... of $35 million in the second quarter of 2013.  ... net income for the three months ended June 30, 2014 ...
(Date:7/31/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced that the Company will receive a ... Asahi Kasei Pharma Corporation (Asahi Kasei). The payment ... a regulatory application to the Japanese Pharmaceutical and ... (collagenase clostridium histolyticum) for the treatment of Dupuytren,s ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:7/31/2014)... July 31, 2014 ReputationChief.Com, a ... new online reputation management service named ‘Remove Pissed ... as organizations get rid of Pissed Consumer Complaints. ... of extensive research. ReputationChief.Com management assigned the responsibility ... those who are struggling in their social or ...
(Date:7/31/2014)... -- A new study by researchers at Sanford-Burnham Medical ... caerulein can convert existing cells in the pancreas into ... The study, published online July 31 in Cell ... treating the estimated 3 million people in the U.S., ... diabetes. , "We have found a promising technique for ...
(Date:7/31/2014)... La Mirada, CA (PRWEB) July 31, 2014 ... California’s leading healthcare providers, strives in maintaining the ... and employers. That is why Healthpointe is offering ... facility to surrounding employers, employees and patients. They ... from insurance carriers. , Healthpointe’s Occupational Medicine services ...
(Date:7/31/2014)... 31, 2014 Dallas Fit Body Boot ... Texas to 3821 Ross Avenue, also in Dallas, in an ... potential members to burn fat and get in great shape ... because he believes that the new space will help his ... results they want as well as accommodate new members interested ...
(Date:7/31/2014)... With a busy lifestyle, it is hard to relax. World ... but to ensure their mental health is equally in check. ... right is key to your body’s health. However, I want everyone ... healthy lifestyle,” expressed Chef Ravi, owner of World Gardens Cafe. Check ... , ", 1. Stop eating lunch at your desk or taking ...
Breaking Medicine News(10 mins):Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2Health News:Occupational Medicine Services Available at Healthpointe’s Perris Facility 2Health News:Dallas Fit Body Boot Camp Moves to New Location, Announces Grand Opening Set for Saturday August 9th 2Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 2Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 3Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 4
... Weight Control Centers in Baltimore ... ... MED ) today announced that Medifast Franchise Systems has sold its,first franchise ... four Medifast Weight Control Centers in the Greater,Baltimore Metropolitan Area., The ...
... ocean and coastal environment is intimately linked to our health. ... Our beaches and coastal waters are increasingly contaminated. Yet there ... natural products and seafood benefits our oceans hold. ... says NOAA,s Juli Trtanj who serves as head of the ...
... Old London(R) Challenges Americans to Get Fit and Live a Healthier ... Lifestyle in ... Food Company, is launching a multi-faceted campaign aimed at,helping women renew their commitment ... feeling women get when they,are able to fit into an old pair of ...
... Management Services Corporation,(ADAMS) announced today that they ... Hospitals in Cleveland, Ohio with a target,completion ... hundred million,dollars will allow University Hospitals to ... also allowing them to provide further,research capabilities ...
... cutting-edge research with renowned clinics to,care for North ... WORTH, Texas, Feb. 18 The University of,North ... The Center for,Cancer and Blood Disorders [ http://www.texascancercare.com/ ... and Blood Disorders. The new,Institute,s goal is to ...
... ST. PAUL, Minn., Feb. 18 Regions Hospital,this week ... a first of,its kind in the region -- with ... unit will work a seven-day-on/seven-day-off schedule,providing improved continuity and ... model involves psychiatrists who will provide care for,patients once ...
Cached Medicine News:Health News:Medifast Franchise Systems Sells First Territory in Baltimore 2Health News:Medifast Franchise Systems Sells First Territory in Baltimore 3Health News:Oceans, coasts and your health: Reducing risks and reaping rewards 2Health News:Old London Launches Skinny Jeans Contest 2Health News:Old London Launches Skinny Jeans Contest 3Health News:Old London Launches Skinny Jeans Contest 4Health News:ADAMS Performs Management Services for University Hospitals' $600 Million Expansion/Renovation Program in Cleveland, OH 2Health News:UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders 2Health News:UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders 3Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
The Performance Knee System is a wide and easy to use system that offers enough options to cover any indication for primary and revision knee surgery, and all this with extensive intraoperative flexi...
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: